Endoscopy

Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD

Retrieved on: 
Wednesday, December 6, 2023
Quality of life, CYP, Kidney, Risk, Heartburn, Enzyme inhibitor, FDA, TIN, Hypertension, Achlorhydria, Magnesium, Liver, PPI, SJS, Magnesium deficiency, Chest pain, Atazanavir, Endoscopy, Impairment, SCAR, Vitamin B12, Malabsorption, Absorption, PDUFA, CDAD, Calcium, New Drug Application, Gastritis, Enzyme, Food and Drug Administration, Clostridioides, Vonoprazan, Patient, Hip, Hypokalemia, Food, Polyp, GERD, Nelfinavir, Toxicity, EGFR, Wrist, Diarrhea, Hypocalcemia, NDA, Abdominal pain, Urinary tract infection, Hypersensitivity, Stevens–Johnson syndrome, Glomus tumor, Spine, Indigestion, Drug, CGA, Lactation, Pharmaceutical industry

The FDA has assigned the application a standard 10-month review with a Prescription Drug User Fee Act (PDUFA) target action date of July 19, 2024.

Key Points: 
  • The FDA has assigned the application a standard 10-month review with a Prescription Drug User Fee Act (PDUFA) target action date of July 19, 2024.
  • “Non-Erosive GERD represents a substantial segment of the U.S. GERD population, affecting millions of individuals and impacting their quality of life.
  • Symptoms impact overall quality of life and can include episodic heartburn, especially at night, regurgitation, problems swallowing, and chest pain.
  • for the maintenance of healing of all grades of Erosive GERD and relief of heartburn associated with Erosive GERD in adults.

Alpha Tau Announces Highly Promising Interim Results from Safety and Feasibility Trial of Alpha DaRT Treatment of Advanced Pancreatic Cancer

Retrieved on: 
Tuesday, November 28, 2023
Associate, Metastasis, Therapeutic endoscopy, Partnership, Neoplasm, Division, Death, Alpha Sigma Tau, Lung, Research, Breast, Radiation, General Hospital, Data, Pancreas, Alpha, Brain, Vulva, JGH, Endoscopy, Clinical trial, News, FRCPC, Pancreatic cancer, CA19-9, Radiation therapy, Interim, Assistant, McGill University, Translational research, Medical school, Patient, Safety, Neck

JERUSALEM, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today the release of interim results from treatment of the first five patients in the Company’s safety and feasibility trial examining the use of Alpha DaRT to treat advanced pancreatic cancer, currently underway at two university hospitals in Montreal, Canada.

Key Points: 
  • Tumor stages of the treated patients ranged from stage II to stage IV, and treated tumors were located in the pancreatic head or neck.
  • With respect to primary outcome measures, the Alpha DaRT procedure was deemed technically successful in all five cases, with Alpha DaRT sources successfully inserted into the target tumor.
  • The first two patients, who had received the fewest number of Alpha DaRT sources, both died approximately three months after treatment, and the deaths were not related to Alpha DaRT treatment.
  • The study primarily examines the safety and feasibility of placing the Alpha DaRT sources in the tumor utilizing endoscopic ultrasound, and the overall safety of the procedure by measuring adverse events.

Global Disposable Endoscope Market Analysis & Forecast to 2028 - Rising Preference of Single Use Endoscopes over Traditional Endoscopes - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 21, 2023
General Health, Health, Medical Devices, Endoscopy, FDA, Incidence, Hospital, GI, Cancer, Fungal infection, Growth, HAI, Investment, Diagnosis, Organization, Medical device

In 2022, the global disposable endoscope market was valued at US$1.58 billion, and is probable to reach US$4.11 billion by 2028.

Key Points: 
  • In 2022, the global disposable endoscope market was valued at US$1.58 billion, and is probable to reach US$4.11 billion by 2028.
  • The growing incidences of hospital-acquired infections (HAI) due to the usage of infected endoscopes is expected to be the key factor driving the global disposable endoscope market during the forecast period.
  • The global disposable endoscope market value is projected to grow at a CAGR of 17.31%, during the forecast period of 2023-2028.
  • Furthermore, availability of robust product portfolio of technologically advanced ureteroscopes has created a lucrative growth potential for disposable endoscope market.

Boomerang Medical's IBD Neuromodulation Study Successfully Completes Enrollment Milestone

Retrieved on: 
Wednesday, December 20, 2023
Alternative Medicine, Health, FDA, Medical Devices, Health Technology, Clinical Trials, Biotechnology, Endoscopy, IBD, Stage 2, Constipation, Multimedia, Physician, Medicine, Research, Diarrhea, Inflammatory bowel disease, Patient satisfaction, Colonoscopy, Abdominal pain, Clinical trial, Trial of the century, University, MPH, Patient, Ulcerative colitis, Pharmaceutical industry

Boomerang Medical, Inc., a women-led bioelectronic medicine company focused on autoimmune diseases, proudly announced the completion of Stage 2 of its FDA-approved pilot study.

Key Points: 
  • Boomerang Medical, Inc., a women-led bioelectronic medicine company focused on autoimmune diseases, proudly announced the completion of Stage 2 of its FDA-approved pilot study.
  • This milestone marks a significant advance in the company’s research as it progresses towards its pivotal study.
  • “This study represents a promising step forward in the quest for expanding the armamentarium for managing IBD.
  • Heather Simonsen, CEO of Boomerang Medical, commented on the recent milestone: “Successfully completing the Stage 2 enrollment for our BOOM-IBD Clinical Trial is a significant step in our research trajectory.

Etron@CES 2024: The Future of AI-Powered Intelligence, Autonomy, Connectivity & Confidentiality

Retrieved on: 
Wednesday, December 20, 2023
Confidentiality, VR, Long, GDPR, Central Hall, Consumer Electronics Show, Research, Robotics, Endoscopy, Electronics, USB, DDR3, Certification, Privacy, LAS, Data-rate units, Observation, LVCC, ISP, Diagnosis, CES, DRAM, Medical device

LAS VEGAS and TAIPEI, Dec. 20, 2023 /PRNewswire/ -- Etron Technology, Inc. (TPEx: 5351), the world's leading IC design company, is announcing its cutting-edge solutions that it will showcase at CES 2024 ‒ electronics with AI capabilities. With the parallel themes of Intelligence, Autonomy, Connectivity, and Confidentiality, the brand is demonstrating its relentless commitment to developing innovative products that enrich lives while advancing its vision of 'Shaping Tomorrow Today'. To experience Etron's demos and engage with in-house experts, visit CES Booth #15459, Central Hall at the LVCC, during January 9-12, CES 2024 period.

Key Points: 
  • With the parallel themes of Intelligence, Autonomy, Connectivity, and Confidentiality, the brand is demonstrating its relentless commitment to developing innovative products that enrich lives while advancing its vision of 'Shaping Tomorrow Today'.
  • DeCloak Intelligences, an Etron company, has been honored with the CES Innovation Awards for two consecutive years.
  • This year's recognition is attributed to its innovative privacy-centric facial recognition and monitoring solution - DeCloakVision.
  • Designed to operate on both cloud and edge computing platforms, it offers flexibility and scalability to meet diverse monitoring needs.

Intelligent Scopes Corp, Subsidiary of Claritas HealthTech, to Lead Global Delivery of CystoSmart™, an AI-Assisted Diagnostic Software for Bladder Cancer Detection in Endoscopic Images

Retrieved on: 
Monday, November 13, 2023
Bladder cancer, Health technology, Research, ISC, Times New Roman, Urology, FDA, Cystoscopy, Gastroenterology, Cancer, AI, Endoscopy, Khoo Teck Puat Hospital, NHG, Image, KTPH, Medical device

Claritas, a leader in image enhancement and AI diagnostic solutions has developed pioneering technology for real-time precision detection of conditions in endoscopic and cystoscopic images.

Key Points: 
  • Claritas, a leader in image enhancement and AI diagnostic solutions has developed pioneering technology for real-time precision detection of conditions in endoscopic and cystoscopic images.
  • Bladder cancer is the 10th most common cancer in the world, and the 6th most common in men.
  • Diagnostics using cystoscopes for examination of the bladder is challenging, and time and resource intensive.
  • Our aim has been to develop an AI diagnostic tool that enhances the accuracy of detection of bladder cancers.

Dr. Jordan Adair of Burlington Emergency & Veterinary Specialists Earns Board Certification, Becoming the Only Exotic Pet Specialist in Vermont

Retrieved on: 
Monday, December 18, 2023
Health, Veterinary, Pets, Consumer, American Veterinary Medical Association, Veterinary medicine, Veterinary specialties, Raptor, Emergency department, Diplomate of National Board, Patient, Pharmacy, Parrot, Animal, DVM, Report, Veterinarian, Primate, Housing, Endoscopy, Certification, BEVS, Poultry

Jordan Adair, DVM, DABVP (Avian) has been certified as a Diplomate by the American Board of Veterinary Practitioners.

Key Points: 
  • Jordan Adair, DVM, DABVP (Avian) has been certified as a Diplomate by the American Board of Veterinary Practitioners.
  • As head of the Exotics Department at Burlington Emergency & Veterinary Specialists (BEVS) in Williston, Vermont, Dr. Adair mastered a rigorous and demanding application process and board examination to obtain Diplomate status.
  • To qualify to sit for the extensive, two-day examination, a veterinarian must complete either an AVMA-accredited residency program or six years of clinical veterinary practice.
  • Owners who have an exotic pet with an emergency health care issue are urged to call the hospital at 802-863-2387 before coming to the Emergency Department.

Sagility Introduces Utilization Management as a Service to Improve Prior Authorization, Mitigate Costs

Retrieved on: 
Thursday, December 14, 2023
General Health, Other Health, Health, Practice Management, Health Insurance, Medicare Advantage, Pressure, UM, Senior, Commercial, Utilization management, URAC, BPM, UMAA, Ratio, CMS, Pain, Medicare, NPS, Endoscopy, MLR, Overalls, Health insurance, Medical device, Nursing, Medicaid, Sagil

Utilization management (UM) and prior authorization, which is the most commonly practiced form of utilization management, are both highly regulated, and health plans can face high penalties and fines when they are out of compliance.

Key Points: 
  • Utilization management (UM) and prior authorization, which is the most commonly practiced form of utilization management, are both highly regulated, and health plans can face high penalties and fines when they are out of compliance.
  • The existing U.S. nursing shortage is one factor exacerbating the pain for payers who struggle to render decisions in a timely manner.
  • In late 2022, CMS proposed a mandate that requires payers to turn around cases faster, as well as provide real-time decisions.
  • Sagility serves Commercial, Medicare Advantage, Medicaid, children’s health plans, and qualified health plans in all 50 states.

Pristine Surgical Announces Full Market Release of Summit™ 4K Single-use Surgical Arthroscope Across the U.S.

Retrieved on: 
Monday, November 27, 2023
Mobile, Wireless, Technology, Medical Devices, Surgery, Medical Supplies, Health Technology, Software, Biotechnology, Hardware, Health, Abdominal ultrasonography, Feedback, Recycling, Surgeon, Pristine, Arthroscopic lavage, Multimedia, Infection, Summit, Hospital, Endoscopy, Medical device

Pristine Surgical , a medical device company dedicated to making endoscopy more efficient, consistent, and safe, has accelerated the launch of its Summit™ 4K single-use surgical arthroscope—the first of its kind.

Key Points: 
  • Pristine Surgical , a medical device company dedicated to making endoscopy more efficient, consistent, and safe, has accelerated the launch of its Summit™ 4K single-use surgical arthroscope—the first of its kind.
  • After an overwhelmingly positive response during its limited market release, Summit™ is now available to hospitals and ambulatory surgery centers across the United States.
  • View the full release here: https://www.businesswire.com/news/home/20231127910489/en/
    Summit™ is a 4K single-use surgical arthroscope designed to simplify endoscopy and is now available to hospitals and ambulatory surgery centers across the United States.
  • It comes pre-installed with Pristine Connect™ software for seamless cloud-connected surgical image and video storage and automated inventory management.

Global Video and Integrated Operating Room Equipment Market Size, Share & Trends Analysis 2024-2030 - ResearchAndMarkets.com

Retrieved on: 
Monday, November 27, 2023
Other Health, Software, Medical Devices, Technology, Hospitals, Health Technology, Surgery, Audio, Video, Nursing, Medical Supplies, Other Technology, Health, ORS, Research, HD, Patient, Workflow, Compound annual growth rate, Endoscopy, Hospital, Integration, Video game

The "Global Video and Integrated Operating Room Equipment Market Size, Share & Trends Analysis 2024-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Video and Integrated Operating Room Equipment Market Size, Share & Trends Analysis 2024-2030" report has been added to ResearchAndMarkets.com's offering.
  • In 2023, the global video and integrated operating room (OR) equipment market exceeded a valuation of $12.2 billion.
  • This comprehensive medical market research involved the analysis of over 80 suppliers of video and integrated OR equipment worldwide.
  • Employing a thorough methodology, we gained insights into market sizes, unit sales, company market shares, and crafted accurate forecasts.